Citi Pharma enters veterinary market with new subsidiary

September 12, 2025 (MLN): Citi Pharma Limited (PSX: CPHL) is entering the veterinary healthcare market with its wholly-owned subsidiary, Citi Veterinary Limited, which has formally commenced trading operations.

The new company is introducing with 32 veterinary products, including vaccines and has already established Letters of Credit (LCs) for 8 of those products to ensure timely supply.

For the financial year 2025-26, Citi Veterinary Limited projects a turnover of approximately Rs1,500 million and a gross profit margin of 13%.

The company aims for a turnover target of Rs10 billion within the next three years, relying on its established supply partnerships in China.

Citi Veterinary is also focused on developing its own production capabilities. A layout plan for a production facility has been submitted to the Drug Regulatory Authority of Pakistan (DRAP), with an inspection expected in December 2025.

The company has acquired machinery and is setting up LCs for additional imports. Trial production is anticipated to begin by the end of Q4 FY 2025-26, with commercial production starting at the beginning of FY 2026-27.

In a significant move, the company also plans to establish Pakistan's first dedicated veterinary API plant during FY 2026-27.

The company anticipates that the commencement of in-house production will increase its gross profit margin to approximately 25% due to stronger value addition and enhanced operational efficiency.

Citi Veterinary Limited is confident this milestone will contribute significantly to Pakistan’s veterinary pharmaceutical industry and strengthen Citi Pharma’s diversified portfolio.

Copyright Mettis Link News